All News
Filter News
Found 806,238 articles
-
Johnson & Johnson Vision Announces Global Collaboration with Menicon to Bring Forward Contact Lenses to Help Manage the Progression of Myopia in Children
4/7/2021
This new collaboration combines expertise from Menicon Co., Ltd., a world-class manufacturer of innovative contact lenses with the science, scale and capabilities of Johnson & Johnson Vision
-
New RestoraFIBRE® Daily Gummies offers convenient source of fibre
4/7/2021
RestoraFIBRE Daily Gummies contains inulin, a prebiotic fibre which helps support a healthy digestive system and promote regularity
-
Biofidelity granted key patent in US for breakthrough cancer diagnostic technology
4/7/2021
Patent supports the unique potential of Biofidelity's technology to deliver ultra-sensitive detection of guideline-recommended tumor markers
-
Fighting Cancer with Personalized Vaccines: OncoDNA and myNEO Join Forces to Unlock the Power of mRNA Therapeutics
4/7/2021
OncoDNA, a theranostic and genomic company specializing in precision medicine, and myNEO, an AI-driven company revolutionizing target identification within immuno-oncology, are thrilled to announce a new collaboration that will revolutionize cancer care.
-
EXACT THERAPEUTICS AS Announces Appointment of Dominic Moreland as Chief Financial Officer
4/7/2021
EXACT THERAPEUTICS AS, a clinical stage precision medicine company utilizing Acoustic Cluster Therapy across multiple therapeutic areas, announced the appointment of Dominic Moreland as Chief Financial Officer who will be based at the London office of EXACT-Tx in White City.
-
PsiOxus Therapeutics Updates Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
4/7/2021
PsiOxus Therapeutics, Ltd. announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® to treat a range of tumor types in late-stage cancer patients.
-
BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808
4/7/2021
BioInvent International AB announced that the U.S. Food and Drug Administration has approved the Investigational New Drug for the Phase I/IIa clinical study of the immuno-modulatory anti-TNFR2 antibody BI-1808.
-
Mission Barns Raises $24M Series A to Scale Up its Cultivated Fat Technology and Build Pilot Production Facility
4/7/2021
Silicon Valley-based cellular agriculture company Mission Barns today announced a $24M Series A to scale up its cultivated fat technology and build a pilot manufacturing plant in the Bay Area.
-
Vizgen Secures $37M Series B Financing to Advance Spatial Genomics Through Commercialization of MERSCOPE™ Platform
4/7/2021
Vizgen, the life science company dedicated to advancing human health by visualizing single-cell spatial genomics information, has closed a $37 million Series B financing.
-
CryoLife to Participate in 20th Annual Needham Virtual Healthcare Conference
4/7/2021
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate in the upcoming 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021.
-
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
4/7/2021
NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the filing of its universal registration document for the financial year ended December 31, 2020 with the French financial market authority (Autorité des marchés financiers or AMF),
-
BioHarvest Sciences Inc. Delivers Record First Quarter Sales Performance of VINIA in Israel
4/7/2021
The total number of VINIA® purchase orders in Q1/2021 also reached a new high of 2,190, an increase of 45% versus Q4/2020.
-
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021
4/7/2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes.
-
X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
4/7/2021
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.
-
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
4/7/2021
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.
-
Adamas to Present at Upcoming Needham Conference
4/7/2021
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on April 12 – 15, 2021.
-
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
4/7/2021
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to release its first quarter 2021, financial results on Wednesday, May 5, 2021.
-
Cabaletta Bio to Present at the 20th Annual Needham Healthcare Conference
4/7/2021
Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the 20th Annual Needham Healthcare Conference
-
Quest Diagnostics To Release First Quarter 2021 Financial Results On April 22
4/7/2021
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2021 financial results on Thursday, April 22, 2021, before the market opens
-
Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference
4/7/2021
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the 20th Annual Needham Virtual Healthcare Conference, taking place April 12-15, 2021.